Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
77°
Rain Shower
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Zymeworks Inc
(NY:
ZYME
)
N/A
UNCHANGED
Last Price
Updated: 7:00 PM EST, Dec 15, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zymeworks Inc
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Earnings Preview: Zymeworks
March 06, 2023
Via
Benzinga
Zymeworks Announces Participation in Upcoming Investor Conferences
February 28, 2023
From
Zymeworks Inc.
Via
Business Wire
Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call
February 21, 2023
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences
January 25, 2023
From
Zymeworks Inc.
Via
Business Wire
$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
January 24, 2023
Although US stocks closed higher on Monday, there were a few notable insider trades.
Via
Benzinga
Analyst Ratings for Zymeworks BC
January 20, 2023
Via
Benzinga
Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks
December 21, 2022
Via
Benzinga
6 Analysts Have This to Say About Zymeworks BC
December 20, 2022
Via
Benzinga
Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer
December 19, 2022
Via
Benzinga
Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer
January 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 19, 2023
Via
Benzinga
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
January 19, 2023
Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
January 19, 2023
We're starting off Thursday with an overview of the biggest pre-market stock movers traders will want to keep an eye on!
Via
InvestorPlace
Around $10M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
January 19, 2023
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
Around $8 Million Bet On Zymeworks? Check Out These 3 Stocks Insiders Are Buying
January 13, 2023
Although US stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
January 04, 2023
From
Zymeworks Inc.
Via
Business Wire
20 Favorite Biotech & Medical Stocks For 2023
December 28, 2022
The way these stocks are setting up, many of them look great and will be at the forefront this coming year.
Via
Talk Markets
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
December 22, 2022
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading.
Via
Benzinga
Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today
December 21, 2022
U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation...
Via
Benzinga
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session
December 21, 2022
Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical...
Via
Benzinga
Zymeworks Announces Participation in Upcoming Investor Conference
December 21, 2022
From
Zymeworks Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
December 20, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 19, 2022
Via
Benzinga
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
December 19, 2022
From
Zymeworks Inc.
Via
Business Wire
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
December 14, 2022
From
Zymeworks Inc.
Via
Business Wire
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
December 09, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks to Transfer Stock Listing to Nasdaq
December 05, 2022
From
Zymeworks Inc.
Via
Business Wire
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
November 30, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END
Via
FinancialNewsMedia
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
November 29, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Participation in Upcoming Investor Conference
November 22, 2022
From
Zymeworks Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.